QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 rbc-capital-maintains-sector-perform-on-moderna-lowers-price-target-to-25

RBC Capital analyst Luca Issi maintains Moderna (NASDAQ:MRNA) with a Sector Perform and lowers the price target from $28 to ...

 leerink-partners-maintains-underperform-on-moderna-raises-price-target-to-18

Leerink Partners analyst Mani Foroohar maintains Moderna (NASDAQ:MRNA) with a Underperform and raises the price target from ...

 walmart-intuit-the-gap-sandisk-and-moderna-why-these-5-stocks-are-on-investors-radars-today

WMT, INTU, GAP, SNDK, MRNA were the stocks seen trending on Thursday, Nov. 20, 2025.

 whats-going-on-with-moderna-stock

Shares of Moderna are falling Thursday. The company made two significant announcements regarding its finances and business stra...

 moderna-closes-5-yr-term-loan-facility-for-up-to-15b-of-capital-from-ares-management-credit-funds

Non-dilutive financing from premier lender bolsters strong balance sheet and provides increased flexibilityCompany reiterates 2...

 moderna-expands-us-manufacturing-capabilities-with-onshoring-of-drug-product-manufacturing-to-existing-moderna-technology-center-in-norwood-massachusetts

New capabilities strengthen U.S. production, completing Moderna's domestic end-to-end mRNA manufacturing networkMore than $...

 merck-makes-big-bet-on-flu-protection-with-cidara-buyout

Merck (NYSE: MRK) to acquire Cidara (NASDAQ: CDTX) for $9.2 billion, diversifying its portfolio with CD388.

 b-of-a-securities-maintains-underperform-on-moderna-lowers-price-target-to-21

B of A Securities analyst Dimple Gosai maintains Moderna (NASDAQ:MRNA) with a Underperform and lowers the price target from ...

 barclays-maintains-equal-weight-on-moderna-lowers-price-target-to-25

Barclays analyst Gena Wang maintains Moderna (NASDAQ:MRNA) with a Equal-Weight and lowers the price target from $31 to $25.

 ai-stocks-slide-again-bitcoin-dips-near-100000-whats-moving-markets-thursday

After a brief and cautious rebound on Wednesday, risk-off sentiment returned sharply on Thursday, with AI-linked stocks leading...

 mrna-vaccine-maker-moderna-lowers-rd-spending-tightens-sales-forecast

Moderna posts a smaller Q3 loss, trims 2025 sales forecast, cuts R&D costs, and boosts cash outlook as COVID vaccine demand...

 moderna-q3-2025-earnings-call-transcript

Moderna reported third-quarter financial results on Thursday. The transcript from the company's earnings call has been prov...

 moderna-narrows-fy2025-sales-guidance-from-1500b-2200b-to-1600b-2000b-vs-1899b-est

Moderna (NASDAQ:MRNA) narrows FY2025 sales outlook from $1.500 billion-$2.200 billion to $1.600 billion-$2.000 billion vs $1.89...

 moderna-q3-eps-051-beats-202-estimate-sales-1016b-beat-886539m-estimate

Moderna (NASDAQ:MRNA) reported quarterly losses of $(0.51) per share which beat the analyst consensus estimate of $(2.02) by 74...

 moderna-stock-is-sliding-monday-whats-going-on

Moderna stock is trading sharply lower Monday afternoon as recent clinical setbacks overshadowed positive pipeline news.

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION